Schott Pharma - Public Comps and Valuation Multiples

Schott Pharma Overview

About Schott Pharma

Schott Pharma AG & CO KGaA is an international provider of drug containment solutions and delivery systems for injectable drugs for pharma, biotech and life-sciences. Its business operates in two segments: Drug Containment Solutions (DCS) and Drug Delivery Systems (DDS). The majority of revenue is being generated from the DCS segment, which includes products like vials, cartridges, and ampoules, and provides customers with sterile and non-sterile options in standard and high-end formats for drug storage. Geographically, the company generates revenue from Europe, the Middle East, Africa (EMEA), Asia and the South Pacific, North America, and South America.

Founded

1884

HQ

Employees

4.8K+

Website

schott-pharma.com

Sectors

Medical Supplies
Drug Delivery Systems

Financials

LTM Revenue $1.2B

LTM EBITDA $326M

EV

$2.7B

Valuation Multiples

Multiples.vc

Valuation Multiples for 15K+ Public Comps

Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.

Browse Valuation Multiples

Schott Pharma Financials

As of November 2025, Schott Pharma reported last 12-month revenue of $1.2B and EBITDA of $326M.

In the same period, Schott Pharma generated $395M in LTM gross profit and $172M in net income.

See Schott Pharma valuation multiples based on analyst estimates

Schott Pharma P&L

In the most recent fiscal year, Schott Pharma reported revenue of $1.2B and EBITDA of $337M.

Schott Pharma expects next 12-month revenue of XXX and NTM EBITDA of XXX

See Schott Pharma valuation multiples based on analyst estimates

	LTM	NTM	Last FY	FY 2025	FY 2026	FY 2027
Revenue	$1.2B	XXX	$1.2B	XXX	XXX	XXX
Gross Profit	$395M	XXX	$390M	XXX	XXX	XXX
Gross Margin	34%	XXX	34%	XXX	XXX	XXX
EBITDA	$326M	XXX	$337M	XXX	XXX	XXX
EBITDA Margin	28%	XXX	29%	XXX	XXX	XXX
EBIT	$231M	XXX	$220M	XXX	XXX	XXX
EBIT Margin	20%	XXX	19%	XXX	XXX	XXX
Net Profit	$172M	XXX	$172M	XXX	XXX	XXX
Net Margin	15%	XXX	15%	XXX	XXX	XXX
Net Debt	XXX	XXX	n/a	XXX	XXX	XXX

Financial data powered by Morningstar, Inc.

.seo-only-financials-wrapper { position: static; left: auto; width: auto; height: auto; overflow: visible; }

Financial performance metrics for Schott Pharma including revenue, profitability, and margin analysis across different time periods. The company reported last twelve months revenue of $1.2B. EBITDA for the last twelve months was $326M. In the most recent fiscal year, Schott Pharma achieved $1.2B in revenue and $337M in EBITDA.
Financial Metric	Last Twelve Months (LTM)	Next Twelve Months (NTM)	Most Recent Fiscal Year	Current Fiscal Year (2025)	Next Fiscal Year (2026)	Two Years Forward (2027)
Total Revenue	$1.2B	Analyst estimates available to subscribers	$1.2B	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
Gross Profit	$395M	Analyst estimates available to subscribers	$390M	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
Gross Profit Margin	33.8% gross margin	Analyst estimates available to subscribers	33.7% gross profit margin	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
EBITDA (Earnings Before Interest, Taxes, Depreciation, Amortization)	$326M	Analyst estimates available to subscribers	$337M	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
EBITDA Margin	27.9% EBITDA margin	Analyst estimates available to subscribers	29.1% EBITDA margin	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
EBIT (Earnings Before Interest and Taxes)	$231M	Analyst estimates available to subscribers	$220M	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
EBIT Margin	19.8% EBIT margin	Analyst estimates available to subscribers	19.0% EBIT margin	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
Net Income (Net Profit)	$172M	Analyst estimates available to subscribers	$172M	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
Net Profit Margin	14.8% net profit margin	Analyst estimates available to subscribers	14.9% net profit margin	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
Net Debt Position	Detailed debt information available to subscribers	Detailed debt information available to subscribers	n/a	Detailed debt information available to subscribers	Detailed debt information available to subscribers	Detailed debt information available to subscribers

Financial Performance Summary for Schott Pharma

This financial data table provides comprehensive performance metrics for Schott Pharma, a company based in Germany. The metrics include revenue, profitability measures, and operational efficiency indicators across multiple time periods.

Recent Performance Highlights

Schott Pharma generated $1.2B in revenue over the last twelve months.
The company achieved $326M in EBITDA over the last twelve months.
Gross profit for the last twelve months was $395M.
Net income over the last twelve months reached $172M.

Fiscal Year Performance

In the most recent fiscal year, Schott Pharma reported $1.2B in total revenue.
Fiscal year EBITDA was $337M.
The company maintained a gross profit margin of 33.7% in the most recent fiscal year.
EBITDA margin for the fiscal year was 29.1%.
Net profit margin reached 14.9% in the most recent fiscal year.

This financial data is sourced from Morningstar, Inc. and represents the most recent available information for Schott Pharma. Forward-looking estimates and detailed financial projections are available through our premium subscription service.

Schott Pharma Stock Performance

Schott Pharma has current market cap of EUR 2.2B (or $2.6B), and EV of EUR 2.3B (or $2.7B).

Market Cap Evolution

Schott Pharma Stock Data

As of December 19, 2025, Schott Pharma's stock price is EUR 15 (or $18).

See Schott Pharma trading valuation data

EV	Market Cap	Price 1D	Price 1M	Price 3M	Price 12M	EPS
$2.7B	$2.6B	XXX	XXX	XXX	XXX	$1.14

Benchmark Trading Valuation Multiples by Industry

Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more

Start Free Trial

Schott Pharma Valuation Multiples

Schott Pharma's trades at 2.4x EV/Revenue multiple, and 8.6x EV/EBITDA.

See valuation multiples for Schott Pharma and 15K+ public comps

Schott Pharma Financial Valuation Multiples

As of December 19, 2025, Schott Pharma has market cap of $2.6B and EV of $2.7B.

Equity research analysts estimate Schott Pharma's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX

Schott Pharma has a P/E ratio of 15.3x.

	LTM	NTM	Last FY	FY 2025	FY 2026	FY 2027
Market cap (current)	$2.6B	XXX	$2.6B	XXX	XXX	XXX
EV (current)	$2.7B	XXX	$2.7B	XXX	XXX	XXX
EV/Revenue	2.3x	XXX	2.4x	XXX	XXX	XXX
EV/EBITDA	8.3x	XXX	8.6x	XXX	XXX	XXX
EV/EBIT	11.7x	XXX	12.2x	XXX	XXX	XXX
EV/Gross Profit	6.8x	XXX	n/a	XXX	XXX	XXX
P/E	15.3x	XXX	15.1x	XXX	XXX	XXX
EV/FCF	44.3x	XXX	33.4x	XXX	XXX	XXX

Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Get Schott Pharma Valuation Multiples

Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.

Start Free Trial

Schott Pharma Margins & Growth Rates

Schott Pharma's last 12 month revenue growth is 5%

Schott Pharma's revenue per employee in the last FY averaged $0.2M, while opex per employee averaged $36K for the same period.

Schott Pharma's rule of 40 is 33% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).

Schott Pharma's rule of X is 40% (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).

See operational valuation multiples for Schott Pharma and other 15K+ public comps

Schott Pharma Operational Valuation Multiples

	LTM	NTM	Last FY	FY 2025	FY 2026	FY 2027
Revenue Growth	5%	XXX	4%	XXX	XXX	XXX
EBITDA Margin	28%	XXX	28%	XXX	XXX	XXX
EBITDA Growth	4%	XXX	4%	XXX	XXX	XXX
Rule of 40	33%	XXX	33%	XXX	XXX	XXX
Bessemer Rule of X	XXX	XXX	40%	XXX	XXX	XXX
Revenue per Employee	XXX	XXX	$0.2M	XXX	XXX	XXX
Opex per Employee	XXX	XXX	$36K	XXX	XXX	XXX
S&M Expenses to Revenue	XXX	XXX	8%	XXX	XXX	XXX
G&A Expenses to Revenue	XXX	XXX	n/a	XXX	XXX	XXX
R&D Expenses to Revenue	XXX	XXX	3%	XXX	XXX	XXX
Opex to Revenue	XXX	XXX	15%	XXX	XXX	XXX

Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Valuation Multiples Across 220+ Verticals

Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!

Digital Therapeutics

Pharma Analytics

Private Equity

ERP Software

Developer Tools

Consumer SaaS

Streaming Platforms

Explore Valuation Multiples by Industry

Start Free Trial